Comparative study of different vaccine platforms for therapeutic vaccination in cancer
Başlık çevirisi mevcut değil.
- Tez No: 852469
- Danışmanlar: DR. SONJA (S.I) BUSCHOW
- Tez Türü: Yüksek Lisans
- Konular: Gastroenteroloji, Gastroenterology
- Anahtar Kelimeler: Belirtilmemiş.
- Yıl: 2022
- Dil: İngilizce
- Üniversite: Erasmus Universiteit Rotterdam
- Enstitü: Yurtdışı Enstitü
- Ana Bilim Dalı: Belirtilmemiş.
- Bilim Dalı: Belirtilmemiş.
- Sayfa Sayısı: 54
Özet
Antigen presentation is one of the cornerstones of our immune system. It is often discussed in terms of fighting against infectious diseases. However, its role in cancer should not be overlooked. The current thought is that tumor cells can be seen as“non-self”since they express antigens that are not seen in healthy cells. However, hurdles created by the tumor cells, such as alterations in antigen presentation, lead to immune evasion of cancer. Therapeutic cancer vaccines aim to feed selected antigens to dendritic cells (DCs) to activate cellular immunity against that particular Tumor Associated Antigen (TAA), which is produced by the tumor cells, and then allow the elimination of the target cells, expressing that antigen. Potential platforms to be used for therapeutic vaccination include, amongst others: whole tumor lysate (WTL)-based vaccines, synthetic long peptides (SLPs)-based vaccines, and mRNA-based vaccines. Until now, it has been unclear which of these vaccine platforms yields the best anti-tumor response. In this study, we used genetically engineered HAP1 cell lines in order to test the aforementioned WTL efficiency in terms of the resulting vaccine antigen immunopeptidome to mimic the peptide repertoire on DCs. To identify Survivin, as a prototype TAA, immunopeptidome in the endogenous model, mass spectrometry-based approach was applied to the model cell line HAP1 which the HLA gene is knocked out, but HLA-A2 and Survivin gene is inserted. To test WTL vaccination, HAP1 cells without any HLA but overexpressing Survivin, were cultured, lysed, and fed to monocyte-derived dendritic cells (moDCs). This approach allowed us to compare antigen presentation and resulting immunopeptidome of the tumor situation to that antigen-fed moDC-based repertoire. However, the exogenous immune repertoire has yet to be obtained. This study, for now, served as a potential pipeline to study different vaccine platforms in terms of their immunopeptidomics in the future. KEYWORDS: Therapeutic vaccination, whole tumor lysate, moDC, HAP1, immunopeptidomics, Survivin, antigen presentation
Özet (Çeviri)
Özet çevirisi mevcut değil.
Benzer Tezler
- Antijenliği artırmaya yönelik yeni yaklaşımlar
Başlık çevirisi yok
FATIMA YÜCEL
Doktora
Türkçe
1997
Tıbbi BiyolojiMarmara ÜniversitesiTıbbi Biyoloji Ana Bilim Dalı
PROF. DR. BEYAZIT ÇIRAKOĞLU
- Kedilerin (feline) calicivirus enfeksiyonunun moleküler epidemiyolojisinin araştırılması
Investigation of the molecular epidemiology of feline calicivirus infection
GÜLİZAR ACAR
Doktora
Türkçe
2023
Veteriner HekimliğiAnkara ÜniversitesiVeterinerlik Viroloji Ana Bilim Dalı
PROF. DR. SEVAL BİLGE DAĞALP
- Peptit yüklü nano aşı formülasyonunun toksoplazma gondii'ye karşı etkinliğinin ın vivo olarak incelenmesi
Peptide loaded nano vaccine formulation and in vivo examination of efficiency against toxoplasma gondii
ZEYNEP KAYA
Yüksek Lisans
Türkçe
2017
BiyomühendislikYıldız Teknik ÜniversitesiBiyomühendislik Ana Bilim Dalı
DOÇ. DR. RABİA ÇAKIR KOÇ
- Sınovac aşısı uygulanan sağlık çalışanlarında aşı sonrası antikor düzeyinin belirlenmesi
Determination of post vaccination antibody levels in HEALTH workers administered with sinovac vaccine
KARDELEN BÜLBÜL
Yüksek Lisans
Türkçe
2022
MikrobiyolojiMersin ÜniversitesiTıbbi Mikrobiyoloji Ana Bilim Dalı
PROF. DR. GÖNÜL ASLAN
- Aşı geliştirilmesinde kullanılmak üzere çeşitli yöntemlerle elde edilen L. infantum antijenlerinin in vivo oluşturduğu immün yanıtın karşılaştırmalı olarak incelenmesi
Comparative investigation of in vivo immune response induced by various L. infantum antigens, obtained that are with different techniques, for vaccine development
ÖZLEM AYŞE ÖZYILMAZ
Yüksek Lisans
Türkçe
2014
BiyomühendislikYıldız Teknik ÜniversitesiBiyomühendislik Ana Bilim Dalı
YRD. DOÇ. DR. MELAHAT BAĞIROVA